Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region

Lamiae Arsalane; Abderrahman Boukhira; Karima Azizan; Youssef Kamouni; Said Zouhair

doi:doi:10.11648/j.ajlm.20190402.11

| Peer-Reviewed

Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region

Lamiae Arsalane, Abderrahman Boukhira, Karima Azizan, Youssef Kamouni, Said Zouhair

Published in American Journal of Laboratory Medicine (Volume 4, Issue 2)

Received: 9 October 2018 Accepted: 5 November 2018 Published: 29 April 2019

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Infection with the hepatitis C virus (HCV) is a major global public health problem. The objectives of this study are to evaluate the seroprevalence of hepatitis C in chronic hemodialysis patients, a category of patients at particular risk of hepatitis C virus transmission, and to identify the main risk factors for infection. This is a prospective study conducted from January 1st, 2015 to December 31st, 2017, including 600 chronic hemodialysis patients treated at 5 centers in the Marrakech region. Patients were tested for anti-HCV antibodies by chemiluminescent microparticulate immunoassay (CMIA). The confirmation is carried out by ELISA. The statistical analysis was performed using the SPSS statistics 17.0 software. The prevalence of anti-HCV antibodies is 15%. There is no statistically significant difference between the groups of HCV-infected and non-HCV-infected patients in terms of age, sex, and number of RBCs transfused. In contrast, the median hemodialysis duration and the number of attended hemodialysis centers were significantly higher in the HCV + group (p <0.001). The factor transfusion long incriminated, loses its importance. On the other hand, seniority in hemodialysis and the number of centers frequented seem to be contributing factors. Adherence to hygiene measures and the rigorous application of prevention recommendations against HCV transmission could further improve the prevalence of hepatitis C in dialysis units.

Published in	American Journal of Laboratory Medicine (Volume 4, Issue 2)
DOI	10.11648/j.ajlm.20190402.11
Page(s)	31-34
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2019. Published by Science Publishing Group

Keywords

Chronic Hemodialysis, Hepatitis C, Prevalence

References

[1]	Global Hepatitis Report 2017. Geneva: World Health Organization; 2017.
[2]	Kamar N, Izopet J, Rostaing L. Prévalence et incidence du virus de l’hépatite C en hémodialyse : dépistage et prévention. Néphrologie & Thérapeutique. 2008 ; 4: 89–91.
[3]	Sekkat S, Kamal N, Benali B, Fellah H, Amazian K, Bourquia A. Prévalence des anticorps anti-VHC et incidence de séroconversion dans cinq centres d’hémodialyse au Maroc. Néphrologie & thérapeutique. 2008 ; 4: 105–10.
[4]	Rahnavardi M, HosseiniMoghaddam SM, AlavianSM. Hepatitis C in hemodialysis patients: Current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am. J. Nephrol. 2008; 28: 628–40.
[5]	Prakash S, Jain A, Sankhwar SN, Usman K, Prasad N, SahaD. Prevalence of hepatitis B & C viruses among patients on hemodialysis in Lucknow, Uttar Pradesh. Clin. Epidemiol. Glob. Heal. 2014; 2: 19–23.
[6]	Alashek W a, McIntyre CW, TaalMW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect. Dis. 2012; 12: 265.
[7]	Vidales-Braz B, da Silva N, Lobato R, Germano F, da Mota L, Barros E. Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients. Virol J. 2015; 12: 8.
[8]	Boulaajaj K, Elomari Y, Elmaliki B, Madkouri B, Zaid D, BenchemsiN. Infectionsvirales : VHC, VHB et VIH chez les hémodialyses, CHU Ibn-Rochd, Casablanca. Néphrologie&thérapeutique. 2005 ; 1: 274–84.
[9]	Abdelaali, B., Omar, M., Taoufik, D., Samir, A., Saad, M., &Benyahia, M. Hepatitis C Viral Prevalence and Seroconversion in Moroccan Hemodialysis Units: Eight Year Follow Up. Journal of Medical Diagnostic Methods, 2013.91.
[10]	El Harraqui R, Karimi I, Benabdellah N, Khanfri N, Bentata Y, Haddiya I. Hépatite virale C en hémodialyse chronique: prévalence et facteurs de risques. Néphrologie & thérapeutique. 2012; 8: 397.
[11]	Benouda A, Boujdiya Z, Ahid S, Abouqal R, Adnaoui M. Prévalence de l’infection par le virus de l'hépatite-C au Maroc et évaluation des tests sérologiques de dépistage pour la prédiction de la virémie. Pathol. Biol. 2009; 57: 368–72.
[12]	Bahadi A, Maoujoud O, Zejjari Y, Alayoud A, Hassani K, Elkabbaj D. Diagnostic et évaluation de l’hépatite virale C chez l'hémodialysé/Diagnosis and evaluation of hepatitis C virus among haemodialysis patients. East. Mediterr. Heal. J. 2013 ; 19: 192.
[13]	Dussol B, Brunet P, Berthezen P. Infection par le virus de l’hépatite C chez les dialysés chroniques multicentrique de la région Sud-Est de la France. XVI e Symp. Gambro, Saint-Étienne. 1995. p. 106–11.
[14]	Su Y, Yan R, Duan Z, Norris JL, Wang L, Jiang Y. Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: A multicenter study in Beijing, China. J. Med. Virol. 2013; 85: 425–32.
[15]	Aman K, Al-Dubai SA, Aman R, Hawash A, Alshagga M, KassimS. Prevalence and associated factors of hepatitis C virus infection among renal disease patients on maintenance hemodialysis in three health centers in Aden, Yemen: a cross sectional study. Saudi J Kidney Dis Transpl. 2015; 26: 380–5.
[16]	Vallet-Pichard A, Pol S. Prise en charge de l’infection par les virus des hépatites B ou C chez l’insuffisant rénal chronique. Néphrologie & thérapeutique. 2015 ; 11: 507–20.
[17]	Dalibon P. L’infection par le virus de l’hépatite C. Actual. Pharm. 2016; 55: 18–20.

Cite This Article

Plain Text BibTeX RIS

APA Style

Lamiae Arsalane, Abderrahman Boukhira, Karima Azizan, Youssef Kamouni, Said Zouhair. (2019). Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region. American Journal of Laboratory Medicine, 4(2), 31-34. https://doi.org/10.11648/j.ajlm.20190402.11

Copy | Download

ACS Style

Lamiae Arsalane; Abderrahman Boukhira; Karima Azizan; Youssef Kamouni; Said Zouhair. Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region. Am. J. Lab. Med. 2019, 4(2), 31-34. doi: 10.11648/j.ajlm.20190402.11

Copy | Download

AMA Style

Lamiae Arsalane, Abderrahman Boukhira, Karima Azizan, Youssef Kamouni, Said Zouhair. Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region. Am J Lab Med. 2019;4(2):31-34. doi: 10.11648/j.ajlm.20190402.11

Copy | Download

@article{10.11648/j.ajlm.20190402.11,
  author = {Lamiae Arsalane and Abderrahman Boukhira and Karima Azizan and Youssef Kamouni and Said Zouhair},
  title = {Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region},
  journal = {American Journal of Laboratory Medicine},
  volume = {4},
  number = {2},
  pages = {31-34},
  doi = {10.11648/j.ajlm.20190402.11},
  url = {https://doi.org/10.11648/j.ajlm.20190402.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajlm.20190402.11},
  abstract = {Infection with the hepatitis C virus (HCV) is a major global public health problem. The objectives of this study are to evaluate the seroprevalence of hepatitis C in chronic hemodialysis patients, a category of patients at particular risk of hepatitis C virus transmission, and to identify the main risk factors for infection. This is a prospective study conducted from January 1st, 2015 to December 31st, 2017, including 600 chronic hemodialysis patients treated at 5 centers in the Marrakech region. Patients were tested for anti-HCV antibodies by chemiluminescent microparticulate immunoassay (CMIA). The confirmation is carried out by ELISA. The statistical analysis was performed using the SPSS statistics 17.0 software. The prevalence of anti-HCV antibodies is 15%. There is no statistically significant difference between the groups of HCV-infected and non-HCV-infected patients in terms of age, sex, and number of RBCs transfused. In contrast, the median hemodialysis duration and the number of attended hemodialysis centers were significantly higher in the HCV + group (p <0.001). The factor transfusion long incriminated, loses its importance. On the other hand, seniority in hemodialysis and the number of centers frequented seem to be contributing factors. Adherence to hygiene measures and the rigorous application of prevention recommendations against HCV transmission could further improve the prevalence of hepatitis C in dialysis units.},
 year = {2019}
}

Copy | Download

TY - JOUR
T1 - Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region
AU - Lamiae Arsalane
AU - Abderrahman Boukhira
AU - Karima Azizan
AU - Youssef Kamouni
AU - Said Zouhair
Y1 - 2019/04/29
PY - 2019
N1 - https://doi.org/10.11648/j.ajlm.20190402.11
DO - 10.11648/j.ajlm.20190402.11
T2 - American Journal of Laboratory Medicine
JF - American Journal of Laboratory Medicine
JO - American Journal of Laboratory Medicine
SP - 31
EP - 34
PB - Science Publishing Group
SN - 2575-386X
UR - https://doi.org/10.11648/j.ajlm.20190402.11
AB - Infection with the hepatitis C virus (HCV) is a major global public health problem. The objectives of this study are to evaluate the seroprevalence of hepatitis C in chronic hemodialysis patients, a category of patients at particular risk of hepatitis C virus transmission, and to identify the main risk factors for infection. This is a prospective study conducted from January 1st, 2015 to December 31st, 2017, including 600 chronic hemodialysis patients treated at 5 centers in the Marrakech region. Patients were tested for anti-HCV antibodies by chemiluminescent microparticulate immunoassay (CMIA). The confirmation is carried out by ELISA. The statistical analysis was performed using the SPSS statistics 17.0 software. The prevalence of anti-HCV antibodies is 15%. There is no statistically significant difference between the groups of HCV-infected and non-HCV-infected patients in terms of age, sex, and number of RBCs transfused. In contrast, the median hemodialysis duration and the number of attended hemodialysis centers were significantly higher in the HCV + group (p <0.001). The factor transfusion long incriminated, loses its importance. On the other hand, seniority in hemodialysis and the number of centers frequented seem to be contributing factors. Adherence to hygiene measures and the rigorous application of prevention recommendations against HCV transmission could further improve the prevalence of hepatitis C in dialysis units.
VL - 4
IS - 2
ER -

Copy | Download

Author Information

Lamiae Arsalane

Bacteriology-Virology Department, Avicenna Military Hospital Marrakech, Faculty of Medicine, Cadi Ayyad University, Marrakech, Morocco
Abderrahman Boukhira

Department of Biochemistry-Chemistry, Avicenna Military Hospital Marrakech, Faculty of Medicine, Cadi Ayyad University, Marrakech, Morocco
Karima Azizan

Bacteriology-Virology Department, Avicenna Military Hospital Marrakech, Faculty of Medicine, Cadi Ayyad University, Marrakech, Morocco
Youssef Kamouni

Bacteriology-Virology Department, Avicenna Military Hospital Marrakech, Faculty of Medicine, Cadi Ayyad University, Marrakech, Morocco
Said Zouhair

Bacteriology-Virology Department, Avicenna Military Hospital Marrakech, Faculty of Medicine, Cadi Ayyad University, Marrakech, Morocco

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Lamiae Arsalane, Abderrahman Boukhira, Karima Azizan, Youssef Kamouni, Said Zouhair. (2019). Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region. American Journal of Laboratory Medicine, 4(2), 31-34. https://doi.org/10.11648/j.ajlm.20190402.11

Copy | Download

ACS Style

Lamiae Arsalane; Abderrahman Boukhira; Karima Azizan; Youssef Kamouni; Said Zouhair. Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region. Am. J. Lab. Med. 2019, 4(2), 31-34. doi: 10.11648/j.ajlm.20190402.11

Copy | Download

AMA Style

Lamiae Arsalane, Abderrahman Boukhira, Karima Azizan, Youssef Kamouni, Said Zouhair. Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region. Am J Lab Med. 2019;4(2):31-34. doi: 10.11648/j.ajlm.20190402.11

Copy | Download

@article{10.11648/j.ajlm.20190402.11,
  author = {Lamiae Arsalane and Abderrahman Boukhira and Karima Azizan and Youssef Kamouni and Said Zouhair},
  title = {Seroprevalence of Hepatitis C in Chronic Hemodialysis Patients in Marrakesh Region},
  journal = {American Journal of Laboratory Medicine},
  volume = {4},
  number = {2},
  pages = {31-34},
  doi = {10.11648/j.ajlm.20190402.11},
  url = {https://doi.org/10.11648/j.ajlm.20190402.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajlm.20190402.11},
  abstract = {Infection with the hepatitis C virus (HCV) is a major global public health problem. The objectives of this study are to evaluate the seroprevalence of hepatitis C in chronic hemodialysis patients, a category of patients at particular risk of hepatitis C virus transmission, and to identify the main risk factors for infection. This is a prospective study conducted from January 1st, 2015 to December 31st, 2017, including 600 chronic hemodialysis patients treated at 5 centers in the Marrakech region. Patients were tested for anti-HCV antibodies by chemiluminescent microparticulate immunoassay (CMIA). The confirmation is carried out by ELISA. The statistical analysis was performed using the SPSS statistics 17.0 software. The prevalence of anti-HCV antibodies is 15%. There is no statistically significant difference between the groups of HCV-infected and non-HCV-infected patients in terms of age, sex, and number of RBCs transfused. In contrast, the median hemodialysis duration and the number of attended hemodialysis centers were significantly higher in the HCV + group (p <0.001). The factor transfusion long incriminated, loses its importance. On the other hand, seniority in hemodialysis and the number of centers frequented seem to be contributing factors. Adherence to hygiene measures and the rigorous application of prevention recommendations against HCV transmission could further improve the prevalence of hepatitis C in dialysis units.},
 year = {2019}
}

Copy | Download